Samsung Electronics Co., Ltd.

Korea Advanced Institute of Science and Technology

Kyung Eun Kim

Sang Yeul Han

Hyung-Chan Kim

Hyo Seon Lee

Kwang Hoon Lee

Seok Kyun Kim

Yoon Sook Lee

Seung Ja Oh

Chung Ho Kim

Mi Young Cho

Chan Kim

Kyung Ah Kim

Gou Young Koh

Yun Ju Jeong

Kwang-Hoon Lee

Yong In Kim

Chungho Kim

An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.

Anti-ANG2 antibody

An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.

Anti-c-Met/anti-Ang2 bispecific antibody

A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.

Fusion polypeptide capable of binding simultaneously to VEGF-C and VEGF-D

An Ang2 specific antibody, a method of inhibiting angiogenesis or a method of treating a disease related to the activation and/or overproduction of Ang2 using the antibody, and a composition for diagnosing a disease related to the activation and/or overproduction of Ang2 including the antibody.

Angiopoietin-2 specific antibodies and uses thereof

A method for the prevention and/or treatment of a disease accompanied by vascular leakage and/or vascular inflammation comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and forms a complex with a Tie2 receptor and Ang2.

Method of blocking vascular leakage using an anti-ANG2 antibody

Anti-Ang2 antibody

Fusion polypeptide inhibiting VEGF-C, VEGF-D and/or angiopoietin-2, and use thereof

Anti-C-Met/anti-Ang2 bispecific antibody

An Ang2 specific antibody, a method of preventing and/or treating a disease related to the activation and/or overproduction (overexpression) of Ang2 by administering the antibody to a subject, and a method of screening a candidate substance for diagnosing, preventing, or treating a disease related to activation or overproduction of Ang2.

Antibody specifically binding to ANG2 and use thereof

An antibody or antigen-binding fragment thereof that specifically binds to and inhibits VEGF-C and uses thereof in a method of inhibiting angiogenesis and a method of preventing, treating, and/or diagnosing a disease associated with activation and/or overexpression of VEGF-C, using the antibody, and a method of detecting the presence of VEGF-C in a sample.

Antibodies or antigen-binding fragments thereof specifically binding to VEGF-C and use thereof

A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.

Combination therapy using anti-C-met antibody and anti-ang-2 antibody

Provided are an anti-Ang-2 antibody or antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang-2), related compositions and pharmaceutical compositions, and methods for using such compositions and pharmaceutical compositions.

Ang-2 specific antibodies and uses thereof

A method of preventing or treating cancer using an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes to a Tie2 receptor while bound with Ang2.

Use of an anti-Ang2 antibody

There are provided an angiopoietin-2 (Ang2) derived peptides, polypeptides, and peptide complexes, and a method for inhibition of binding between Ang2 and integrin and prevention and/or treatment of a disease caused by the activation of Ang2 or the binding between Ang2 and integrin using the peptide, polypeptides, and peptide complexes.

Growing community of inventors

Yongin-si, South Korea

Kyung Eun Kim